Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease

References

• Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD. A call for action: increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer. 2017;123(19 ):3662–3672. doi:10.1002/cncr.3090328759108
   PubMed Web of Science ®Google Scholar
• Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2 ):579–585. doi:10.1182/blood-2004-01-033815039286
   PubMed Web of Science ®Google Scholar
• Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31(21 ):2662–2670. doi:10.1200/JCO.2012.46.865223797000
   PubMed Web of Science ®Google Scholar
• Wang H, Shao Z. Research progress on treatment of myelodysplastic syndromes with demethylating drugs. Chin J Clin Oncol. 2015;42(18 ):895–899.
   Google Scholar
• Kon Kim T, Gore SD, Zeidan AM. Epigenetic therapy in acute myeloid leukemia: current and future directions. Semin Hematol. 2015;52(3 ):172–183. doi:10.1053/j.seminhematol.2015.04.00326111464
   PubMed Web of Science ®Google Scholar
• Cruijsen M, Hobo W, van der Velden WJFM, et al. Addition of 10-day decitabine to fludarabine/total body irradiation conditioning is feasible and induces tumor-associated antigen-specific T cell responses. Biol Blood Marrow Transplant. 2016;22(6 ):1000–1008. doi:10.1016/j.bbmt.2016.02.00326860635
   PubMed Web of Science ®Google Scholar
• Potter VT, Iacobelli S, van Biezen A, et al. Comparison of intensive chemotherapy and hypomethylating agents before allogeneic stem cell transplantation for advanced myelodysplastic syndromes: a study of the myelodysplastic syndrome subcommittee of the chronic malignancies working party of the European Society for Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016;22(9 ):1615–1620. doi:10.1016/j.bbmt.2016.05.02627264633
   PubMed Web of Science ®Google Scholar
• Pusic I, Choi J, Fiala MA, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2015;21(10 ):1761–1769. doi:10.1016/j.bbmt.2015.05.02626055299
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang J, Liu H, et al. Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Natl Med J China. 2015;95(12 ):920–924.
   Google Scholar
• Minakata D, Fujiwara S, Ito S, et al. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: a propensity score analysis. Leuk Res. 2016;42:82–87. doi:10.1016/j.leukres.2015.12.01326790727
   PubMed Web of Science ®Google Scholar
• Xu L, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018;11(1 ):33. doi:10.1186/s13045-018-0564-x29495966
   PubMedGoogle Scholar
• Mo XD, Kong J, Zhao T, et al. Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant. 2014;20(12 ):2023–2028. doi:10.1016/j.bbmt.2014.08.02325196855
   PubMed Web of Science ®Google Scholar
• Lai YR, Chen YH, Hu DM, et al. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). J Hematol Oncol. 2014;7:59. doi:10.1186/s13045-014-0059-325139202
   PubMed Web of Science ®Google Scholar
• Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45(2 ):255–260. doi:10.1038/bmt.2009.13419543327
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhao H, Zhang X, et al. Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen-mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23(5 ):830–835. doi:10.1016/j.bbmt.2017.01.08528189902
   PubMed Web of Science ®Google Scholar
• Fan LY, Hu SY, Xiao PF, et al. [The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies]. Zhonghua Nei Ke Za Zhi. 2018;57(9 ):679–682. doi:10.3760/cma.j.issn.0578-1426.2018.09.01130180454
   PubMedGoogle Scholar
• Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116(1 ):129–139. doi:10.1182/blood-2009-12-25725320424188
   PubMed Web of Science ®Google Scholar
• De Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116(23 ):5420–5431. doi:10.1002/cncr.2550020672358
   PubMed Web of Science ®Google Scholar
• Ma Y, Qu C, Dai H, et al. Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia. Bone Marrow Transplant. 2019. doi:10.1038/s41409-019-0677-z
   Google Scholar
• El-Cheikh J, Massoud R, Fares E, et al. Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. Bone Marrow Transplant. 2017;52(6 ):918–921. doi:10.1038/bmt.2017.3128368381
   PubMed Web of Science ®Google Scholar
• Schroeder T, Rautenberg C, Kruger W, et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI – a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2018;97(2 ):335–342. doi:10.1007/s00277-017-3185-529151133
   PubMed Web of Science ®Google Scholar
• Kim DY, Lee JH, Park YH, et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant. 2012;47(3 ):374–379. doi:10.1038/bmt.2011.8621478916
   PubMed Web of Science ®Google Scholar
• Fransolet G, Ehx G, Somja J, et al. Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. J Hematol Oncol. 2016;9(1 ). doi:10.1186/s13045-016-0281-2
   PubMedGoogle Scholar
• Landman S, Cruijsen M, Urbano PCM, et al. DNA methyltransferase inhibition promotes Th1 polarization in human CD4(+)CD25(high) FOXP3(+) regulatory T cells but does not affect their suppressive capacity. J Immunol Res. 2018;2018:4973964. doi:10.1155/2018/497396429850630
   PubMed Web of Science ®Google Scholar
• Moon C, Kim SH, Park KS, et al. Use of epigenetic modification to induce FOXP3 expression in naïve T cells. Transplant Proc. 2009;41(5 ):1848–1854. doi:10.1016/j.transproceed.2009.02.10119545742
   PubMed Web of Science ®Google Scholar
• Stamou P, Marioli D, Patmanidi AL, et al. Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease. Cytotherapy. 2017;19(4 ):521–530. doi:10.1016/j.jcyt.2017.01.00428162915
   PubMed Web of Science ®Google Scholar
• Wang X, Wang J, Yu Y, et al. Decitabine inhibits T cell proliferation via a novel TET2-dependent mechanism and exerts potent protective effect in mouse auto and allo-immunity models. Oncotarget. 2017;8(34 ):56802–56815. doi:10.18632/oncotarget.1806328915632
   PubMedGoogle Scholar
• Sánchez-Abarca LI, Gutierrez-Cosio S, Santamaría C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010;115(1 ):107–121. doi:10.1182/blood-2009-03-21039319887673
   PubMed Web of Science ®Google Scholar
• Li X, Mei Q, Nie J, Fu X, Decitabine: HW. A promising epi-immunotherapeutic agent in solid tumors. Expert Rev Clin Immunol. 2015;11(3 ):363–375. doi:10.1586/1744666X.2015.100239725578329
   PubMed Web of Science ®Google Scholar
• Engel N, Rank A. Epigenomics in hematopoietic transplantation: novel treatment strategies. Epigenomics. 2011;3(5 ):611–623. doi:10.2217/epi.11.8022126249
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Fujii N, Imada M, et al. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2017;19(4 ):514–520. doi:10.1016/j.jcyt.2016.12.00728139337
   PubMed Web of Science ®Google Scholar
• Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14 ):3361–3369. doi:10.1182/blood-2011-09-37704422234690
   PubMed Web of Science ®Google Scholar
• Chan HW, Kurago ZB, Stewart CA, et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med. 2003;197(2 ):245–255. doi:10.1084/jem.2002112712538663
   PubMed Web of Science ®Google Scholar
• Coral S, Sigalotti L, Gasparollo A, et al. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2ʹ-deoxycytidine (5-AZA-CdR). J Immunother. 1999;22(1 ):16–24. doi:10.1097/00002371-199901000-000039924695
   PubMed Web of Science ®Google Scholar
• Hambach L, Ling KW, Pool J, et al. Hypomethylating drugs convert HA-1 negative solid tumors into targets for stem cell based immunotherapy. Blood. 2009;113(12 ):2715–2722. doi:10.1182/blood-2008-05-15895619096014
   PubMed Web of Science ®Google Scholar
• Krishnadas DK, Bao L, Bai F, Chencheri SC, Lucas K. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. Tumor Biol. 2014;35(6 ):5753–5762. doi:10.1007/s13277-014-1764-9
   PubMedGoogle Scholar
• Liu Y, Kuick R, Hanash S, Richardson B. DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol. 2009;130(2 ):213–224. doi:10.1016/j.clim.2008.08.00918945643
   PubMed Web of Science ®Google Scholar
• Santourlidis S, Trompeter HI, Weinhold S, et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol. 2002;169(8 ):4253–4261. doi:10.4049/jimmunol.169.8.425312370356
   PubMed Web of Science ®Google Scholar
• Stübig T, Badbaran A, Luetkens T, et al. 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm. 2014;2014:1–12. doi:10.1155/2014/418292
   Web of Science ®Google Scholar
• Wang J, Zhou J, Zheng HF, Fu ZZ. Effect of decitabine on immune regulation in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22(5 ):1448–1452.25338605
   PubMedGoogle Scholar
• Yang H, Bueso-Ramos C, Dinardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6 ):1280–1288. doi:10.1038/leu.2013.35524270737
   PubMed Web of Science ®Google Scholar
• Daurkin I, Eruslanov E, Vieweg J, Kusmartsev S. Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2ʹ-deoxycytidine. Cancer Immunol Immunother. 2010;59(5 ):697–706. doi:10.1007/s00262-009-0786-419882154
   PubMed Web of Science ®Google Scholar